oncology cme

To receive up to 2.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/2022chest-podcast

This dynamic live symposium, led by top experts in the field of pulmonary medicine and NSCLC, will take attendees on a deep dive into the sentinel role of the pulmonologist in the NSCLC management paradigm, exploring adaptive mechanisms to optimize collaborative strategies in a patient centric manner.

Learning Objectives

• Review the sentinel placement of the pulmonologist in the management of NSCLC, including their principal role in diagnostics, disease staging, and molecular testing.
• Evaluate clinical and patient-value driven factors that may help inform nodule evaluation and diagnostic strategies for pulmonologists, thus ensuring “the right tissue in the right amount from the right place for the right patient.”
• Demonstrate knowledge of guideline recommendations and practical considerations for the use of EBUS-TNBA techniques by pulmonologists, emphasizing the fundamentals of safely and effectively obtaining adequate tissue for diagnosis and molecular characterization.
• Describe the evolving role of targeted therapy and immunotherapy in NSCLC and analyze currently FDA-approved therapeutics across the NSCLC disease continuum, highlighting the role of molecular testing for guiding treatment and individualizing patient care.
• Explore the established utility of next-generation sequencing (NGS) and discuss the potential for emerging “next-generation” biomarkers in the NSCLC management paradigm.
• Apply patient-centric, evidence-supported collaborative care strategies to real-world, case-based scenarios in order to elucidate the pivotal role of the pulmonologist on the multidisciplinary team across the NSCLC continuum of care.

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from AstraZeneca.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/ebc-gr-podcast

Learning Objectives

• Review the epidemiology and clinical characteristics of HR+, HER2- early-breast cancer (EBC), and identify patients at an elevated risk of disease recurrence as a means of guiding treatment.
• Appraise the current treatment landscape in HR+, HER2- EBC, including the established and emerging evidentiary base for novel therapies in the adjuvant setting, expert consensus guidelines, and FDA-approved indications.
• Recognize treatment-related adverse events associated with oral therapies used in HR+, HER2- EBC and implement evidence-supported mitigation and management protocols.
• Using real-world patient case examples, design on-label treatment plans for HR+, HER2- EBC at high risk for recurrence, emphasizing the critical need for effective communication and coordination strategies among the multidisciplinary community-based breast cancer care team.
• Evaluate adaptive approaches for promoting adherence and persistence to oral anticancer therapies, highlighting common reasons for noncompliance and the impact of patient counseling and shared decision-making (SDM).

Presented by:

Hope S. Rugo, MD
Professor, Division of Hematology/Oncology
Director, Breast Oncology Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from Lilly.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/ovarian-gr-podcast

Learning Objectives

• Review recent updates to national guideline recommendations in ovarian cancer treatment and testing and discuss health equity issues that may hinder ovarian cancer patients from receiving the current standard of care.
• Appraise landmark and emerging safety and efficacy data with PARP inhibitors in the treatment of ovarian cancer, with a focus on most recent recommendations and rationale for the use of PARP inhibitors in the first-line maintenance setting.
• Analyze the unique toxicity profiles among PARP inhibitor therapies and important considerations for both monitoring and managing adverse events.
• Use an interactive, multi-disciplinary approach to discuss challenging cases regarding the appropriate selection of treatment based on clinical data and guidelines, the use of predictive biomarkers, the management of adverse events, and strategies to mitigate modifiable healthcare disparities in ovarian cancer patients.

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from GSK.

Learning Objectives

• Discuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies community-based clinicians can employ to promote equitable care and outcomes for all patients.
• Review antibody-drug conjugate (ADC) structure, mechanism of action, and real-world clinical considerations, including dosing, administration, and toxicity management, for community oncology clinicians using ADCs to manage TNBC. 
• Examine completed, ongoing, and planned clinical trial data for ADCs as part of the evolving and expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.
• Using a patient case-driven approach, design evidence-based treatment plans for patients with TNBC, with an emphasis on the placement of novel therapies in the shifting TNBC treatment calculus and the effective integration of socioeconomic and other non-biologic factors into equitable cancer care.   
   

Supported by independent educational grant from Gilead.

Presented by Creative Educational Concepts, LLC.